MX2022010958A - Moleculas procesadas por la proteasa. - Google Patents

Moleculas procesadas por la proteasa.

Info

Publication number
MX2022010958A
MX2022010958A MX2022010958A MX2022010958A MX2022010958A MX 2022010958 A MX2022010958 A MX 2022010958A MX 2022010958 A MX2022010958 A MX 2022010958A MX 2022010958 A MX2022010958 A MX 2022010958A MX 2022010958 A MX2022010958 A MX 2022010958A
Authority
MX
Mexico
Prior art keywords
protease
protein molecules
processed molecules
molecules
processed
Prior art date
Application number
MX2022010958A
Other languages
English (en)
Spanish (es)
Inventor
Ercole Rao
Thomas Langer
Sandra Weil
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2022010958A publication Critical patent/MX2022010958A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022010958A 2020-03-05 2021-03-05 Moleculas procesadas por la proteasa. MX2022010958A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305233 2020-03-05
PCT/EP2021/055673 WO2021176090A1 (en) 2020-03-05 2021-03-05 Protease-processed molecules

Publications (1)

Publication Number Publication Date
MX2022010958A true MX2022010958A (es) 2022-10-07

Family

ID=71096648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010958A MX2022010958A (es) 2020-03-05 2021-03-05 Moleculas procesadas por la proteasa.

Country Status (15)

Country Link
US (1) US20230279151A1 (enExample)
EP (1) EP4114865B1 (enExample)
JP (1) JP7766608B2 (enExample)
KR (1) KR20220150345A (enExample)
CN (1) CN115210265A (enExample)
AU (1) AU2021231327A1 (enExample)
BR (1) BR112022017542A2 (enExample)
CA (1) CA3170452A1 (enExample)
DK (1) DK4114865T3 (enExample)
ES (1) ES3068539T3 (enExample)
IL (1) IL295958A (enExample)
MX (1) MX2022010958A (enExample)
PL (1) PL4114865T3 (enExample)
TW (1) TW202146463A (enExample)
WO (1) WO2021176090A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025199278A2 (en) * 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked multispecific antigen-binding molecules with cleavable linkers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252096A1 (en) * 2005-04-26 2006-11-09 Glycofi, Inc. Single chain antibody with cleavable linker
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CN103068846B9 (zh) * 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN112225798B (zh) * 2011-05-17 2023-07-18 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
EP2729488A4 (en) * 2011-07-06 2015-01-14 Medimmune Llc PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
KR101963230B1 (ko) * 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
EP3197916A2 (en) * 2014-09-25 2017-08-02 Amgen Inc. Protease-activatable bispecific proteins
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins

Also Published As

Publication number Publication date
KR20220150345A (ko) 2022-11-10
ES3068539T3 (en) 2026-06-01
JP2023516380A (ja) 2023-04-19
US20230279151A1 (en) 2023-09-07
PL4114865T3 (pl) 2026-05-25
CA3170452A1 (en) 2021-09-10
BR112022017542A2 (pt) 2022-10-18
DK4114865T3 (da) 2026-04-27
CN115210265A (zh) 2022-10-18
JP7766608B2 (ja) 2025-11-10
IL295958A (en) 2022-10-01
TW202146463A (zh) 2021-12-16
EP4114865B1 (en) 2026-01-28
AU2021231327A1 (en) 2022-10-27
WO2021176090A1 (en) 2021-09-10
EP4114865A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
MX2022006893A (es) Conjugado anticuerpo-farmaco anti-claudina y uso farmaceutico del mismo.
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
AR114541A1 (es) Constructos de anticuerpos para cldn18.2 y cd3
MX2022000991A (es) Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
GT200900264A (es) Moléculas y métodos para modular la pro-proteina
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
MX2018015252A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
ECSP11011115A (es) Anticuerpos anti-pd-l1 y su uso para mejorar la función de células t
GT200900268A (es) Polipeptidos de factor vii modificados y usos de los mismos .
ECSP23073436A (es) Anticuerpos anti-nectina-4 y usos de los mismos
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
UY31563A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
UY31562A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
BR112017008304A2 (pt) tripeptidil peptidases tolerantes à prolina e seus usos
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
MX2023014679A (es) Peptidos grapados y metodos para su obtencion.
BR112021008012A2 (pt) Conjugados de anticorpo de cisteína engenheirada-fármaco com ligantes contendo peptídeo
CL2021002838A1 (es) Anticuerpo anti-bcma conjugado, composiciones que comprenden el mismo, y métodos de fabricación y uso del mismo.
AR087094A1 (es) Formulaciones que estabilizan proteinas
CO2024007013A2 (es) Isoxazolidinas como inhibidores de ripk1 y uso de estas
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp